<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704587</url>
  </required_header>
  <id_info>
    <org_study_id>ProFaCo</org_study_id>
    <secondary_id>METC 06-p-47</secondary_id>
    <secondary_id>MEC 08-02-030</secondary_id>
    <secondary_id>NL14215.096.06</secondary_id>
    <nct_id>NCT00704587</nct_id>
  </id_info>
  <brief_title>Prognostic Factors for All Types of Cancer Combined</brief_title>
  <acronym>ProFaCo</acronym>
  <official_title>Flow Cytometrical Analysis of the Human Immune System to Assess Tumor-related Material Piling up in Activated Macrophages in All Relevant Cancer Types.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrium Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate every possible applicability of flow cytometrical
      analysis in the intracellular detection of tumor-related material in activated macrophages in
      the broadest range of cancer types.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>screening and followup</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">520</enrollment>
  <condition>Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      white cells

      tissue

      plasma

      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        all patients diagnosed or suspected of cancerous conditions in the broadest sense of the
        word
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (Suspicion of) presence of cancer in the broadest sense of the word

          -  Must be able to understand and sign written informed consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Japink, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atrium Medical Centre Parkstad, Heerlen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atrium Medical Centre Parkstad</name>
      <address>
        <city>Heerlen</city>
        <state>Limburg</state>
        <zip>6401 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2008</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Medical Center</investigator_affiliation>
    <investigator_full_name>Dennis Japink</investigator_full_name>
    <investigator_title>drs</investigator_title>
  </responsible_party>
  <keyword>cancer occurence</keyword>
  <keyword>cancer recurrence</keyword>
  <keyword>neo-adjuvant treatment response measurement</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

